Lanicemine

170px
170px
Systematic (IUPAC) name
(1S)-1-Phenyl-2-pyridin-2-ylethanamine
Clinical data
Legal status	Development terminated
Identifiers
CAS Number	153322-05-5
ATC code	none
PubChem	CID: 9794203
IUPHAR/BPS	7681
ChemSpider	7969970
Chemical data
Formula	C13H14N2
Molecular mass	198.26 g/mol
SMILES N[C@H](C1=CC=CC=C1)CC2=NC=CC=C2
InChI InChI=1S/C13H14N2/c14-13(11-6-2-1-3-7-11)10-12-8-4-5-9-15-12/h1-9,13H,10,14H2/t13-/m0/s1 Key:FWUQWDCOOWEXRY-ZDUSSCGKSA-N

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist developed by AstraZeneca, which was being studied for the management of severe and treatment-resistant depression. It was originally developed as a neuroprotective agent, but was redeveloped as an antidepressant following the observation that the NMDA receptor antagonist ketamine has potent antidepressant effects, but also has hallucinogenic side effects which make it unsuitable for use as an antidepressant in most circumstances. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.

See also

• AD-1211
• AV-101
• CERC-301
• Diphenidine
• Ephenidine
• Esketamine
• Lefetamine
• Memantine
• Methoxphenidine (MXP)
• MT-45
• NRX-1074
• Rapastinel